SIRT1 activation promotes mitophagy via PINK1/Parkin, reduces oxidative stress, and decreases DPR levels in cellular models. Marginally feasible given resveratrol's failure in AD trials, but warrants testing with selective activators in C9-specific models.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMIDValidation: 0%3 supporting / 3 opposing
✓For(3)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
3
MECH 3CLIN 3GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
SIRT1 activator (SRT2104) extends survival in TDP-…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-28 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Test Preregistration: Therapeutic Hypotheses in Neurodegeneration
Hypothesis 1: Microglial TREM2 Activation as Therapeutic Target in Alzheimer's Disease
Title: TREM2 agonism will reduce amyloid-associated neurotoxicity by promoting microglial phagocytosis and metabolic reprogramming
Mechanism: TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a microglia-specific receptor essential for microglial response to amyloid plaques. Agonist-mediated activation enhances amyloid clearance, reduces dystrophic neurites, and shifts microglia from a disease-associated (DAM) to home
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Weakest link: R47H is a loss-of-function variant—agonism restores WT signaling, but does pharmacologic agonism recapitulate endogenous activation? The therapeutic window may be narrow.
Confounds:
5xFAD mice have aggressive amyloid deposition; microglial dynamics differ in human AD where plaques form over decades
TREM2 agonism may enhance phagocytosis of vulnerable synapses, not just plaques (PMID 30742032 showed microglial engulfment of excitatory terminals)
AL002c is hypothetica
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
The Theorist presented 7 mechanistically-plausible hypotheses; the Skeptic's critiques substantially weakened most. Below I assess feasibility across five dimensions for each surviving hypothesis.
H1: TREM2 Agonism in AD
| Dimension | Assessment | |-----------|------------| | Druggability | Tractable — antibody therapeutics suit cell-surface receptors. AL002c (from Alector) already in Phase II for AD. Fc-mediated agonism is a proven mechanism. | | Biomarkers/Models | Model concern: 5xFAD ha
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD", "description": "Genetic or pharmacologic NRF2 activation using CDDO-EA or sulforaphane upregulates ARE gene transcription (NQO1, HO-1, GCLM), restoring redox homeostasis impaired across major neurodegenerative diseases. Prioritized as most practical near-term opportunity due to multiple clinical-stage compounds and favorable risk profile.", "target_gene": "NFE2L2 (NRF2)", "dimension_scores": { "evidence_strength": 0.72, "novelty": 0.55, "f
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.